# Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

> **NCT00037791** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 180 (—)

## Conditions studied

- Neoplasms
- Thrombocytopenia
- Multiple Myeloma
- Lymphoma, Malignant

## Interventions

- **DRUG:** (PN-152,243)/PN-196,444

## Key facts

- **NCT ID:** NCT00037791
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** —
- **Final completion:** 2002-09
- **Target enrollment:** 180 (—)
- **Last updated:** 2006-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037791, "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00037791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*